AS

Ameya Sameer Kulkarni

Active Director Director DIN 10469791
DIN 10469791 First appointment Jan 2024
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jan 2024
Shareholding value •••• Premium profile

About Ameya Sameer Kulkarni

Data last updated:

Ameya Sameer Kulkarni is a Director at Kmedi Pharma Private Limited (since 2024). Kmedi Pharma Private Limited reported revenue of ₹8 Lakh (FY 2025).

DIN 10469791
Primary Designation Director
First Appointment 18 Jan 2024
Oldest Company Age 2 yrs
Largest company Kmedi Pharma Private Limited · ₹8 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Kmedi Pharma Private Limited U47721MH2024PTC417497
Director18 Jan 20242024₹8 Lakh (FY 2025)Active

Board colleagues of Ameya Sameer Kulkarni

NameDINCompanyDesignation
Vaishali Sameer Kulkarni10469790Kmedi Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Kmedi Pharma Private Limited
Premium access

Shareholding and investment profile for Ameya Sameer Kulkarni

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ameya Sameer Kulkarni

Ameya Sameer Kulkarni currently holds 1 directorship: Kmedi Pharma Private Limited (Director, since 18 Jan 2024, revenue ₹8 Lakh (FY 2025)).

Ameya Sameer Kulkarni was first appointed on 18 Jan 2024 as Director at Kmedi Pharma Private Limited.

The current boards of Ameya Sameer Kulkarni's companies include Vaishali Sameer Kulkarni (Kmedi Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available